A. Grothey

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2021 .

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7

P. Novotny, J. Sloan, C. Loprinzi, 2008 .

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

A. Grothey, B. Childs, H. Hochster, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

J. Guinney, M. Teufel, P. Wirapati, 2015 .

612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

C. Tournigand, R. Goldberg, V. Heinemann, 2020 .

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Reply to A. Chan et al

J. Sloan, C. Loprinzi, A. Grothey, 2011 .

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019 .

Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction?

A. Grothey, R. Corcoran, 2020, JAMA oncology.

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

A. Grothey, M. Fakih, F. Ciardiello, 2020 .

Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement.

A. Grothey, S. Kopetz, B. Clary, 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

N. Wolmark, E. Van Cutsem, R. Goldberg, 2019, Journal of Clinical Oncology.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Journal of Clinical Oncology.

LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer

A. Grothey, F. Ciardiello, R. Hofheinz, 2015 .

Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC).

H. Lenz, A. Grothey, R. Wilcox, 2015 .

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly oxaliplatin (OXA) plus high dose 24h 5-FU infusion/FA in patients with advanced colorectal cancer (CRC)

A. Grothey, P. Reichardt, K. Ridwelski, 2001 .

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Molecular profile of BRCA-mutated biliary tract cancers

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

J. Meyerhardt, James D. Murphy, C. Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.

A. Ganser, A. Grothey, M. Flasshove, 1990, Onkologie.

Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study

D. Sargent, J. Berlin, A. Grothey, 2008 .

Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

A. Grothey, H. Wolf, H. Schmoll, 2005, European journal of haematology.

Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials

R. Kerbel, A. Grothey, 2015, Nature Reviews Clinical Oncology.

PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER

M. Ychou, J. Tabernero, A. Grothey, 2013 .

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

J. Desai, J. Schellens, J. Tabernero, 2018 .

Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

A. Grothey, M. Banck, 2009, Clinical Cancer Research.

Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review.

B. Costello, A. Grothey, J. Hecht, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Costs of treatment of colorectal cancer in different settings in Germany

M. Stauch, A. Grothey, U. Kleeberg, 2004, The European Journal of Health Economics, formerly: HEPAC.

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer

B. Somer, A. Grothey, Evan S. Glazer, 2020, Annals of Surgical Oncology.

[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].

A. Grothey, H. Schmoll, L. Kellermann, 2002, Medizinische Klinik.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

R. Greil, A. Hinke, A. Grothey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pre-Emptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.

J. Sloan, B. Pasche, M. Lacouture, 2021, The oncologist.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis

S. Kubicka, A. Grothey, T. Seufferlein, 2004 .

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

M. Shah, E. Van Cutsem, J. Tabernero, 2022, Clinical colorectal cancer.

Reply to S.A. Kesikli et al

D. Sargent, A. Grothey, J. Franko, 2012 .

yetanotherchangetotheseventhAmericanJointCancerCommittee/ UnionInternationaleContreleCancerwillgreatlyimproveourability to provide better care. Then again, we hope that molecular predictors of disease velocity and treatment response will provide better staging, optimistically in the foreseeable futu

D. Sargent, A. Grothey, J. Franko, 2012 .

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017 .

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity

D. Sargent, H. McLeod, C. Fuchs, 2005 .

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC).

A. Grothey, H. Hurwitz, S. Sarkar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

J. Blay, G. Demetri, E. Van Cutsem, 2014, The oncologist.

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Risk assessment in stage II colon cancer: to treat or not to treat?

A. Grothey, 2010, Oncology.

A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer.

A. Grothey, S. Siena, T. Yoshino, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

D. Sargent, R. Goldberg, A. Grothey, 2011, The oncologist.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

D. Sargent, R. Goldberg, A. Grothey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclooxygenase-2: a novel target for cancer chemotherapy?

A. Grothey, W. Dempke, H. Schmoll, 2001, Journal of Cancer Research and Clinical Oncology.

A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES

L. Hartmann, R. Vile, J. Pulido, 2012, Retina.

First- and second-line therapy of metastatic colorectal cancer

A. Grothey, S. Terstriep, 2006, Expert review of anticancer therapy.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

J. Meyerhardt, James D. Murphy, C. Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes & Control.

The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors

A. Grothey, W. Dempke, W. Voigt, 1999, Journal of Cancer Research and Clinical Oncology.

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)

D. Sargent, R. Goldberg, A. Shields, 2016, The Oncologist.

Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers

P. Philip, R. Goldberg, H. Lenz, 2021, Molecular Cancer Therapeutics.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

John L Marshall, P. Philip, R. Goldberg, 2018, Molecular Cancer Research.

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype

R. Goldberg, H. Lenz, A. Shields, 2020, Cancers.

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

A. Grothey, Axel Grothey, George P. Kim, 2008, Biologics : targets & therapy.

Xin Wang, Fang Yang, Shouhao Zhou, 2019, JAMA oncology.

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

G. Mills, J. Marshall, R. Broaddus, 2021, Clinical Cancer Research.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Review: Medical treatment of advanced colorectal cancer in 2009

A. Grothey, 2009, Therapeutic advances in medical oncology.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Afsaneh Barzi, Katrina Pedersen, Jeannine S McCune, 2019, The Lancet. Oncology.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Ahmed Kamel, Howard S Hochster, Christopher G Willett, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Drug rechallenge and treatment beyond progression—implications for drug resistance

Daniel J. Sargent, Robert S. Kerbel, D. Sargent, 2013, Nature Reviews Clinical Oncology.

Systemic Therapy for Elderly Patients with Gastrointestinal Cancer

D. Sargent, A. Grothey, J. Hubbard, 2011, Clinical Medicine Insights. Oncology.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer

A. Grothey, 2011, Oncology.

Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines.

J. Sanabria, A. Grothey, W. Yong, 2021, The lancet. Gastroenterology & hepatology.

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.

J. Tabernero, A. Grothey, M. Fakih, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer

D. Berry, M. Oberley, P. Stafford, 2020, Clinical Cancer Research.

Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

R. Goldberg, H. Lenz, A. Shields, 2019, The oncologist.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

D. Sargent, C. Bokemeyer, E. Van Cutsem, 2018, European journal of cancer.

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

R. Riechelmann, A. Grothey, 2017, Therapeutic advances in medical oncology.

NCCN Rectal Cancer , Version 2 . 2018 Clinical Practice Guidelines in Oncology

J. Meyerhardt, James D. Murphy, C. Willett, 2018 .

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

R. Labianca, E. Oki, T. Yamanaka, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Clinical colorectal cancer.

Evolving role of regorafenib for the treatment of advanced cancers.

Jean-Yves Blay, Takayuki Yoshino, J. Blay, 2020, Cancer treatment reviews.

C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines

H. Ji, P. McCrea, Dihua Yu, 2000, Oncogene.

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

Amber C. Donahue, J. Desai, Zhou Zhu, 2021 .

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

J. Desai, E. Van Cutsem, J. Tabernero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jesse S. Voss, James X. Sun, A. Grothey, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

James X. Sun, P. Stephens, V. Miller, 2016, The oncologist.

Cancer Stem Cells and Cancer Stem Cell Inhibitors in Gastrointestinal Cancers

A. Grothey, J. Hubbard, 2016 .

Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability–High Colorectal Cancer

A. Grothey, 2012, Current Colorectal Cancer Reports.

Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Tsung-Teh Wu, R. Diasio, A. Grothey, 2012, Clinical Cancer Research.

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

R. Labianca, J. Berlin, K. Haustermans, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The continuum of care: a paradigm for the management of metastatic colorectal cancer.

A. Benson, E. Van Cutsem, R. Diasio, 2007, The oncologist.

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

A. Grothey, F. Kabbinavar, P. Flynn, 2012, European journal of cancer.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 administered in combination with FOLFIRI with and without bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).

A. Grothey, D. Jonker, C. Li, 2016 .

MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach

E. Van Cutsem, M. Ducreux, J. Tabernero, 2018, Journal of Cancer Research and Clinical Oncology.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

J. Tabernero, A. Grothey, S. Kopetz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Defining the role of panitumumab in colorectal cancer

A. Grothey, 2006 .

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

J. Tabernero, A. Grothey, R. Yaeger, 2020 .

Regorafenib in the treatment of colorectal cancer

A. Grothey, N. Majithia, 2016, Expert opinion on pharmacotherapy.

Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting.

A. Grothey, 2012, Clinical advances in hematology & oncology : H&O.

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set

D. Mytelka, E. Van Cutsem, J. Tabernero, 2018, ESMO Open.

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

J. Haerting, A. Grothey, W. Fleig, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent developments in therapy for gastrointestinal cancers

A. Grothey, 2011 .

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

V. Lowe, M. Hung, M. Borad, 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.

A. Grothey, George P. Kim, 2005, Clinical colorectal cancer.

Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma

P. Philip, H. Lenz, A. Shields, 2020, Journal of surgical oncology.

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib

A. Grothey, Yiyi Yan, 2015, OncoTargets and therapy.

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

E. Van Cutsem, J. Tabernero, A. Grothey, 2022, JCO precision oncology.

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, A. Grothey, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

J. Hecht, A. Grothey, S. Kopetz, 2015, Cancer treatment reviews.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials

D. Sargent, S. Mandrekar, A. Grothey, 2019, Contemporary clinical trials communications.

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group

G. Curigliano, A. Grothey, R. Wolff, 2020, The oncologist.

Treatment options for advanced pancreatic cancer: a review

A. Grothey, R. Warsame, 2012, Expert review of anticancer therapy.

Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC).

P. Philip, A. Shields, J. Marshall, 2020 .

Metastatic extramammary Paget's disease responding to weekly paclitaxel

A. Grothey, Vania H Phuoc, 2015, BMJ Case Reports.

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

D. Sargent, R. Goldberg, A. Grothey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

D. Sargent, S. Thibodeau, R. Goldberg, 2014, Journal of the National Cancer Institute.

Clinical Trial Designs for Prospective Validation of Biomarkers

D. Sargent, S. Mandrekar, M. Goetz, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

A review of oxaliplatin and its clinical use in colorectal cancer

R. Goldberg, A. Grothey, 2004, Expert opinion on pharmacotherapy.

Cancer of the Small Bowel

T. Smyrk, A. Grothey, R. McWilliams, 2006 .

Evolution of Cancer Care in Response to the COVID‐19 Pandemic

N. Ibrahim, G. Curigliano, A. Grothey, 2020, The oncologist.

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

D. Sargent, R. Goldberg, A. Grothey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer.

A. Grothey, D. Shibata, N. VanderWalde, 2021, JCO oncology practice.

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2020, Journal of Clinical Oncology.

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting

A. Grothey, A. Vanderwalde, L. Schwartzberg, 2021, Gynecologic Oncology.

Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting

A. Grothey, A. Vanderwalde, L. Schwartzberg, 2020, Journal of personalized medicine.

Does Stage II Colorectal Cancer Need to Be Redefined?

A. Grothey, 2011, Clinical Cancer Research.

Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breastancer

P. McCrea, A. Sahin, A. Grothey, 2000, British Journal of Cancer.

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

C. Loprinzi, A. Grothey, R. McWilliams, 2019, Supportive Care in Cancer.

Imaging , Diagnosis , Prognosis Association of HER 2 / ErbB 2 Expression and Gene Ampli fi cation with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Qian Shi, Tsung-Teh Wu, Robert B. Jenkins, 2012 .

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2021, JAMA.

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

E. Van Cutsem, A. Grothey, A. Ohtsu, 2014, Investigational New Drugs.

Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.

D. Nagorney, T. Smyrk, A. Grothey, 2018, The oncologist.

New Adjuvant Trial Designs in Colon Cancer

D. Sargent, A. Grothey, J. Hubbard, 2015, Current Colorectal Cancer Reports.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

A. Degramont, J. Meyerhardt, C. Bokemeyer, 2022, JNCI Cancer Spectrum.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

R. Goldberg, H. Lenz, J. Tabernero, 2016 .

Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)

M. Ychou, A. Grothey, F. Ciardiello, 2016 .

Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.

A. Grothey, S. Kopetz, A. Dasari, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiemetic Efficacy of an Oral Suspension of Granisetron plus Dexamethasone and Influence of Quality of Life on Risk for Nausea and Vomiting

A. Grothey, K. Jordan, C. Fibich, 2005, Oncology Research and Treatment.

Where do we stand with 5-fluorouracil?

A. Grothey, W. Dempke, H. Schmoll, 1999, Seminars in oncology.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

R. Labianca, J. Meyerhardt, V. Torri, 2020, The Lancet. Oncology.

Oxaliplatin-safety profile: neurotoxicity.

A. Grothey, 2003, Seminars in oncology.

North Central Cancer Treatment Group--achievements and perspectives.

E. Perez, J. Buckner, D. Sargent, 2008, Seminars in oncology.

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

P. Philip, W. El-Deiry, R. Goldberg, 2020, ESMO Open.

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

A. Grothey, S. Dakhil, S. Alberts, 2020, Therapeutic advances in medical oncology.

Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

M. Ychou, E. Van Cutsem, H. Lenz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment options for advanced pancreatic cancer

A. Grothey, R. Warsame, E. Rev, 2012 .

Adolescent and young adult colorectal cancer.

A. Grothey, J. Hubbard, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

C. Tournigand, D. Sargent, R. Stephens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer

A. Grothey, C. Allegra, 2012, Therapeutic advances in medical oncology.

Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage.

A. Grothey, S. Philippou, R. Voigtmann, 1998, British Journal of Cancer.

Low E-cadherin and β-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas

A. Grothey, L. Milas, T. Akimoto, 1999, Clinical & Experimental Metastasis.

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients.

J. Buckner, D. Sargent, J. Sloan, 2015, SOJ anesthesiology & pain management.

Distinctive Tumor Biology of MSI-High Colorectal Cancer

A. Grothey, B. Kipp, N. Majithia, 2015, Current Colorectal Cancer Reports.

Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX.

A. Grothey, B. Burnette, 2010 .

Anal Carcinoma , Version 2 . 2018 Clinical Practice Guidelines in Oncology

J. Meyerhardt, A. Benson, James D. Murphy, 2018 .

Choosing the right biologic agent in the 'continuum-of-care era': A clinical perspective

A. Grothey, C. Cremolini, 2013 .

EGFR antibodies in colorectal cancer: where do they belong?

A. Grothey, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)

P. Novotny, J. Sloan, C. Loprinzi, 2016, The Lancet. Oncology.

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

C. Loprinzi, A. Grothey, S. Dakhil, 2016, Supportive Care in Cancer.

Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement

M. Choti, T. Pawlik, C. Charnsangavej, 2006, Annals of Surgical Oncology.

Exploring racial differences in outcome and treatment for metastatic colorectal cancer

D. Sargent, J. Berlin, A. Grothey, 2012, Cancer.

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is obesity an advantage in patients with colorectal cancer?

A. Grothey, P. Kasi, S. Y. Zafar, 2015, Expert review of gastroenterology & hepatology.

Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis

J. Haerting, A. Grothey, W. Fleig, 2007 .

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study

A. Grothey, T. Bekaii-Saab, P. Kasi, 2019, Front. Oncol..

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer

H. Lenz, A. Grothey, H. Hurwitz, 2018, British Journal of Cancer.

Role of Biologics in First-Line Treatment of Colorectal Cancer.

A. Grothey, A. Mahipal, 2016, Journal of oncology practice.

Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.

A. Grothey, T. Bekaii-Saab, G. Prager, 2020, Clinical advances in hematology & oncology : H&O.

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2023, European journal of cancer.

Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

A. Grothey, J. Yi, D. Purdie, 2007 .

Curable Metastatic Colorectal Cancer

A. Grothey, Matthew J Eadens, 2011, Current oncology reports.

RECENT DEVELOPMENTS IN REGORAFENIB TREATMENT FOR GASTROINTESTINAL CANCERS: PRESENTATIONS AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2016

J. Blay, A. Grothey, G. Prager, 2016 .

The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases

M. Kendrick, A. Grothey, T. Halfdanarson, 2010, Cancer journal.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

R. Greil, A. Hinke, A. Grothey, 2008, Clinical colorectal cancer.

A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)

C. Tournigand, D. Sargent, R. Goldberg, 2007 .

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

D. Sargent, A. Grothey, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of Clinical Oncology.

Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers

A. Grothey, M. Kohli, D. Jassal, 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.

M. Oberley, H. Lenz, A. Shields, 2023, The Lancet. Oncology.

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

L. Pusztai, A. Grothey, Z. Demko, 2022, JCO precision oncology.

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.

M. Oberley, H. Lenz, A. Shields, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB).

R. Goldberg, A. Shields, J. Marshall, 2020 .

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers

A. Grothey, S. Gholami, M. Cho, 2021, Current Colorectal Cancer Reports.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic web‐based models for stage II and III colon cancer

D. Sargent, A. Bardia, C. Loprinzi, 2011, Cancer.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

D. Sargent, R. Diasio, Adam M. Lee, 2016, Pharmacogenetics and genomics.

3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

D. Sargent, A. Grothey, D. Purdie, 2007 .

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

A. Grothey, S. Kopetz, M. Malhotra, 2021, BMJ Open.

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay

A. Grothey, S. Kopetz, Z. Wainberg, 2019, JCO precision oncology.

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2020 .

Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!).

D. Sargent, A. Bardia, C. Loprinzi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.

M. Kendrick, D. Nagorney, A. Grothey, 2017, The oncologist.

A new prognostic and predictive tool for shared decision making in stage III colon cancer.

A. Shields, P. Bruzzi, A. Grothey, 2020, European journal of cancer.

Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).

Edward S. Kim, R. Goldberg, H. Lenz, 2019, Journal of Clinical Oncology.

Sequencing beyond the second-line setting in metastatic colorectal cancer.

J. Marshall, A. Grothey, T. Bekaii-Saab, 2019, Clinical advances in hematology & oncology : H&O.

Explaining the unexplainable: EGFR antibodies in colorectal cancer.

H. Lenz, A. Grothey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.

E. Van Cutsem, M. Ducreux, J. Tabernero, 2021 .

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

A. Grothey, H. Hurwitz, M. Fakih, 2019, Annals of Oncology.

New chemotherapy approaches in colorectal cancer

A. Grothey, Axel Grothey, H. Schmoll, 2001, Current opinion in oncology.

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

D. Sargent, B. Bot, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should oncologists routinely discuss fertility preservation with cancer patients of childbearing age?

A. Grothey, Shawnta Coleman, 2011, Mayo Clinic proceedings.

Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer

P. McCrea, A. Sahin, A. Grothey, 1999 .

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

James D. Murphy, C. Willett, C. Fuchs, 2015 .

LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

M. Shah, A. Grothey, R. Xu, 2017 .

Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.

D. Sargent, A. Bardia, C. Loprinzi, 2010, Seminars in oncology.

Antiangiogenic therapy in cancer: a new era has begun.

A. Grothey, Axel Grothey, 2005, Oncology.

HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC).

R. Diasio, A. Grothey, F. Sinicrope, 2011, Journal of Clinical Oncology.

Disease-free survival in colon cancer: still relevant after all these years!

D. Sargent, A. Grothey, A. de Gramont, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

J. Berlin, A. Grothey, F. Kabbinavar, 2010, Oncology.

Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX)

D. Sargent, R. Goldberg, A. Grothey, 2007, Cancer.

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

G. Demetri, J. Bruix, A. Grothey, 2021, Cancer management and research.

Reply to D.J. Stewart

D. Sargent, A. Grothey, 2010 .

Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.

D. Sargent, S. Mandrekar, J. Bogaerts, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Daniel J Sargent, Somnath Sarkar, D. Sargent, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer.

D. Sargent, A. Grothey, T. André, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.

A. Grothey, H. Hurwitz, M. Fakih, 2018 .

Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.

M. Borad, A. Grothey, R. McWilliams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting.

A. Grothey, C. Lautenschläger, H. Schmoll, 2010, European journal of cancer care.

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

C. Earle, A. Grothey, A. Venook, 2015 .

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer

Z. Trajanoski, R. Goldberg, H. Lenz, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Chemotherapy for advanced gastric cancer.

J. Haerting, A. Grothey, W. Fleig, 2005, The Cochrane database of systematic reviews.

Developments in combination chemotherapy for colorectal cancer

M. Goetz, A. Grothey, 2004, Expert review of anticancer therapy.

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Rectal Cancer, Version 2.2015.

James D. Murphy, C. Willett, Yi-Jen Chen, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Prescriber adherence to antiemetic guidelines with the new agent trifluridine-tipiracil

A. Grothey, A. Jatoi, J. Hubbard, 2017 .

O-0032PHASE III RANDOMIZED, PLACEBO(PL)-CONTROLLED, DOUBLE-BLIND STUDY OF INTRAVENOUS CALCIUM/MAGNESIUM (CAMG) TO PREVENT OXALIPLATIN-INDUCED SENSORY NEUROTOXICITY (SNT), N08CB: AN ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY STUDY1

C. Loprinzi, A. Grothey, S. Dakhil, 2013 .

Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.

C. Loprinzi, A. Grothey, S. Dakhil, 2013 .

517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

J. Desai, J. Schellens, A. Grothey, 2017 .

Colon Cancer , Version 2 . 2018 Featured Updates to the NCCN Guidelines

J. Meyerhardt, James D. Murphy, C. Willett, 2018 .

Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.

P. Philip, W. El-Deiry, R. Goldberg, 2019, Journal of Clinical Oncology.

Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

V. Lowe, N. Foster, A. Grothey, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

V. Torri, M. Ychou, E. Van Cutsem, 2016, ESMO Open.

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

A. Grothey, M. Fakih, F. Ciardiello, 2023, Nature communications.

Chemotherapy in Merkel Cell Carcinoma with Distant Metastasis — Proposal of a Pan-European Clinical Trial

P. Helmbold, A. Grothey, 2003 .

Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741

D. Sargent, R. Goldberg, A. Grothey, 2007 .

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.

C. Bokemeyer, E. Van Cutsem, C. Punt, 2021, Journal of the National Cancer Institute.

Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance).

C. Loprinzi, A. Grothey, S. Dakhil, 2014 .

Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned.

A. Grothey, T. Halfdanarson, 2012, The oncologist.

Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.

D. Sargent, S. Mandrekar, J. Bogaerts, 2015, Journal of the National Cancer Institute.

Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases

A. Grothey, S. Alberts, 2007 .

A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience.

D. Nagorney, A. Grothey, C. Hallemeier, 2018, The oncologist.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

A. Grothey, A. Ohtsu, H. Hochster, 2016, BMC Cancer.

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

A. Grothey, H. Hurwitz, W. Novotny, 2004 .

A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7)

S. Mandrekar, M. Goetz, R. Goldberg, 2005 .

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

A. Grothey, Q. Shi, J. Paul, 2018, The New England journal of medicine.

Oxaliplatin plus oral fluoropyrimidines in colorectal cancer.

M. Goetz, A. Grothey, 2004, Clinical colorectal cancer.

Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry

A. Grothey, J. Yi, D. Purdie, 2007 .

2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy

A. Grothey, F. Ciardiello, R. Hofheinz, 2015 .

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Lindsay A. Renfro, Herbert I. Hurwitz, L. Diaz, 2017, Clinical Cancer Research.

NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).

A. Grothey, I. Abbass, A. Vanderwalde, 2021, Journal of Clinical Oncology.

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Schellens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of malignant pericardial effusion with 32P-colloid

A. Grothey, W. Dempke, W. Voigt, 1999, British Journal of Cancer.

Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.

A. Grothey, C. Verschraegen, A. Kudelka, 1998, Anti-Cancer Drugs.

New lessons from "old" chemotherapy in colorectal cancer.

D. Sargent, A. Grothey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy in elderly patients with colorectal cancer.

C. Bokemeyer, M. Aapro, A. Grothey, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR inhibition in colorectal cancer with liver metastasis.

A. Grothey, 2020, Clinical advances in hematology & oncology : H&O.

Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients

P. Philip, W. El-Deiry, R. Goldberg, 2021, npj Precision Oncology.

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies

M. Ychou, A. Grothey, H. Lenz, 2012 .

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

E. Van Cutsem, A. Grothey, F. Kabbinavar, 2023, Cancers.

S-1 in colorectal cancer: a new standard of care?

A. Grothey, 2012, The Lancet. Oncology.

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib

A. Grothey, Yiyi Yan, Yiyi Yan, 2015 .

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.

O. Margalit, W. Harmsen, H. Lenz, 2022, European journal of cancer.

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

D. Sargent, S. Thibodeau, H. McLeod, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C.

J. T. Reynolds, B. Bot, A. Grothey, 2010 .

3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)

J. Hainsworth, A. Grothey, J. Yi, 2007 .

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes and Control.

LBA-10MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach

M. Ducreux, A. Grothey, P. O'dwyer, 2015 .

C. Tournigand, D. Sargent, C. Punt, 2016, The Lancet. Oncology.

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib

A. Grothey, Yiyi Yan, 2015, OncoTargets and therapy.

Neoadjuvantand Adjuvant Treatment for Colorectal Cancer

A. Grothey, 2011 .

Drug rechallenge and treatment beyond progression—implications for drug resistance

D. Sargent, R. Kerbel, A. Grothey, 2013, Nature Reviews Clinical Oncology.

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

F. Meric-Bernstam, R. Broaddus, A. Grothey, 2018 .

Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).

P. Philip, W. El-Deiry, R. Goldberg, 2019, Journal of Clinical Oncology.

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

N. Staff, C. Loprinzi, A. Grothey, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study.

A. Grothey, H. Schmoll, K. Jordan, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?

A. Grothey, S. Gholami, 2020, The Lancet. Oncology.

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.

R. Schilsky, M. Bertagnolli, R. Goldberg, 2015 .

Does Stage II Colorectal Cancer Need to Be Redefined?

A. Grothey, 2011, Clinical Cancer Research.

Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance)

D. Sargent, J. Singh, P. Novotny, 2018, International journal of statistics in medical research.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

A. Grothey, A. Cercek, M. Fakih, 2017 .

BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.

T. Larson, A. Grothey, T. Bekaii-Saab, 2017 .